PREVALENCE, MANAGEMENT AND OUTCOME OF MULTIDRUGS RESISTANT TUBERCULOSIS: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/77ebps02Keywords:
Tuberculosis, MDR-TB, management, outcome.Abstract
Background: Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB), is an important obstacle to global TB control. The failure to diagnose and effectively treat MDR/RR-TB patients perpetuate ongoing MDR/RR-TB transmission in the community and can amplify the MDR/RR-TB burden.
The aim: The aim of this study to show about prevalence, management and outcome of multidrug resistant tuberculosis.
Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. This search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed, SagePub, and Sciencedirect were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: Five publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles.
Conclusion: The success of any national program can only be ascertained by studying the outcomes of treatment regimes in patients with MDR-TB enrolled in different DOTS-plus sites of the country.
References
Gupta N, Jorwal P. Treatment outcomes associated with multidrug-resistant tuberculosis. J Glob Infect Dis. 2018;10(3):125–8.
Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Saudi Med J. 2015;36(12):1463–71.
Phuong NTM, Nhung N V., Hoa NB, Thuy HT, Takarinda KC, Tayler-Smith K, et al. Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Heal Action. 2016;6(1):25–31.
Asgedom SW, Teweldemedhin M, Gebreyesus H. Prevalence of Multidrug-Resistant Tuberculosis and Associated Factors in Ethiopia: A Systematic Review. J Pathog. 2018;2018:1–8.
Caminero JA, Cayla JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnosis and Treatment of Drug-Resistant Tuberculosis. Arch Bronconeumol. 2017;53(9):501–9.
Zhang MW, Zhou L, Zhang Y, Chen B, Peng Y, Wang F, et al. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res [Internet]. 2021;26(1):1–10. Available from: https://doi.org/10.1186/s40001-021-00502-0
Wang Z, Hou Y, Guo T, Jiang T, Xu L, Hu H, et al. Epidemiological characteristics and risk factors of multidrugresistant tuberculosis in Luoyang, China. Front Public Heal. 2023;11.
Belachew T, Yaheya S, Tilahun N, Gebrie E, Seid R, Nega T, et al. Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. Infect Drug Resist. 2022;15(May):2891–9.
Seung KJ, Keshavjee S, Rich ML. Drug-Resistant Tuberculosis. 2015;1–20.
Li Q, Shi CX, Lu M, Wu L, Wu Y, Wang M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Med (United States). 2020;99(30):E21296.
Lecai J, Mijiti P, Chuangyue H, Qian G, Weiguo T, Jihong C. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study. Front Public Heal. 2023;11(June):1–9.
Panford V, Kumah E, Kokuro C, Adoma PO, Baidoo MA, Fusheini A, et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, crosssectional study. BMJ Open. 2022;12(7):1–9.
Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant
tuberculosis treatment in West Java Indonesia: A retrospective cohort study. PLoS One [Internet]. 2021;16(2 February):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0246284
Sharma N, Khanna A, Chandra S, Basu S, Chopra K, Singla N, et al. Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014): A retrospective record-based study. Indian J Med Res[Internet].2020;151(6):598.Availablefrom:https://journals.lww.com/ijmr/Fulltext/2020/51060/Trends___tre atment_outcomes_of_multidrug_resistant.14.aspx
Tembo BP, Malangu NG. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana. BMC Infect Dis. 2019;19(1):1–8.
Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-Resistant TB (MDR-TB) and Extensively DrugResistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. 2023;15(2):1–15.
Sambas MFMK, Rabbani U, Al-Gethamy MMM, Surbaya SH, Alharbi FFI, Ahmad RGA, et al. Prevalence and determinants of multidrug-resistant tuberculosis in makkah, saudi arabia. Infect Drug Resist. 2020;13:4031–8.
Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis. PLoS One [Internet]. 2022;17(6 June):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0270272
Sheetu Singh, Neeraj Sharma, Udaiveer Singh, Tejraj Singh, Mangal DK, Singh V. Nasopharyngeal wash in
preventing and treating upper respiratory tract infections: Could it prevent COVID‑19? Lung India [Internet].
;35(1):41–6. Available from: https://pubmed.ncbi.nlm.nih.gov/32367847/
Ambaye GY, Tsegaye GW. Factors Associated with Multi-Drug Resistant Tuberculosis among TB Patients in Selected Treatment Centers of Amhara Region: A Case-Control Study. Ethiop J Health Sci. 2021;31(1):25–34.
Brode SK, Varadi R, McNamee J, Malek N, Stewart S, Jamieson FB, et al. Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients. Can Respir J. 2015;22(2):97–102.
Diriba G, Alemu A, Yenew B, Tola HH, Gamtesa DF, Mollalign H, et al. Epidemiology of extensively drugresistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and metaanalysis. Int J Infect Dis. 2023;132:50–63.
Wakjira MK, Sandy PT, Mavhandu-Mudzusi AH. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS One [Internet]. 2022;17(2 February):1–12. Available from: http://dx.doi.org/10.1371/journal.pone.0262318
Omer AA, Meshesha MD, Ajema AT, Yoo SD. Treatment Outcome of MDR/RR TB in a Resource-Constrained Setup: A Four-Year Retrospective Analysis. Infect Drug Resist. 2022;15(August):4707–19.
Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022;12(September):1–18.
Pradipta IS, Van’T Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JWC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015. Antimicrob Resist Infect Control. 2019;8(1):1–12.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
